/ACRS
ACRS Stock - Aclaris Therapeutics, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$3.14+1.95%
+$0.06 (+1.95%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+242.4%upside
Target: $10.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACRS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.11 – $3.17
TARGET (TP)$10.75
STOP LOSS$2.89
RISK/REWARD1:30.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.63
52W High$3.48
52W Low$1.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $18.72M | $31.25M | $29.75M | $6.76M | $6.48M |
| Gross Profit | $15.93M | $13.17M | $17.79M | $2.05M | $1.35M |
| Gross Margin | 85.1% | 42.1% | 59.8% | 30.3% | 20.8% |
| Operating Income | $-141,932,000 | $-97,357,000 | $-89,854,000 | $-89,723,000 | $-50,912,000 |
| Net Income | $-132,065,000 | $-88,481,000 | $-86,908,000 | $-90,865,000 | $-51,015,000 |
| Net Margin | -705.5% | -283.1% | -292.1% | -1344.0% | -787.0% |
| EPS | $-1.71 | $-1.27 | $-1.33 | $-1.60 | $-1.20 |
Company Overview
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
90%
Hold / Neutral
1
10%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish1 Neutral/Bearish
Price Targets
$16
Average Target
↑ 412.4% Upside
Now
$6
Low
$16
Average
$32
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 10th 2025 | Piper Sandler | Resumed | Overweight | $6 |
| May 28th 2025 | Wedbush | Initiation | Outperform | $8 |
| March 18th 2025 | Cantor Fitzgerald | Resumed | Overweight | - |
| December 23rd 2024 | H.C. Wainwright | Upgrade | Buy | $20 |
| November 20th 2024 | Cantor Fitzgerald | Upgrade | Overweight | - |
| November 19th 2024 | Leerink Partners | Upgrade | Outperform | $7← $2 |
| November 19th 2024 | BTIG Research | Upgrade | Buy | $8 |
| November 19th 2024 | Jefferies | Upgrade | Buy | $7← $2 |
| November 18th 2024 | Piper Sandler | Upgrade | Overweight | $13← $3 |
| January 22nd 2024 | H.C. Wainwright | Downgrade | Neutral | - |
| November 13th 2023 | William Blair | Downgrade | Market Perform | - |
| October 3rd 2023 | Evercore ISI | Initiation | Outperform | $22 |
| December 14th 2022 | Stifel | Initiation | Buy | $29 |
| December 1st 2022 | Goldman | Initiation | Buy | $25 |
| October 6th 2022 | BTIG Research | Initiation | Buy | $32 |
Earnings History & Surprises
ACRSBeat Rate
67%
Last 18 quarters
Avg Surprise
+4.1%
EPS vs Estimate
Beats / Misses
12/5
1 met exactly
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
+18.9%
$-0.30vs$-0.37
Q2 24
+14.3%
$-0.24vs$-0.28
Q3 24
+21.1%
$-0.15vs$-0.19
Q4 24
-37.5%
$-0.11vs$-0.08
Q1 25
-11.1%
$-0.10vs$-0.09
Q2 25
+29.4%
$-0.12vs$-0.17
Q3 25
0.0%
$-0.13vs$-0.13
Q4 25
+7.7%
$-0.12vs$-0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.15 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.13 | $-0.12 | +7.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.13 | $-0.13 | 0.0% | = MET |
Q2 2025 | May 8, 2025 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.09 | $-0.10 | -11.1% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.08 | $-0.11 | -37.5% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.37 | $-0.30 | +18.9% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.48 | $-0.41 | +14.6% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.45 | $-0.42 | +6.7% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.44 | $-0.42 | +4.5% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.46 | $-0.41 | +10.9% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.39 | $-0.30 | +23.1% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.36 | $-0.31 | +13.9% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.39 | $-0.31 | +20.5% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.36 | $-0.37 | -2.8% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-0.27 | $-0.35 | -29.6% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.26 | $-0.34 | -30.8% | ✗ MISS |
Latest News
Aclaris Therapeutics Added To The Nasdaq Biotechnology Index, Effective At The Close Of Trading Today, December 19, 2025
📈 PositiveBenzinga•Dec 19, 2025, 09:02 PM
Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:24 PM
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 11:39 AM
Aclaris Therapeutics To Host 2025 R&D Day In Midtown, New York On October 14 To Discuss Its Progress In Addressing Therapeutic Gaps In Immuno-Inflammatory Markets
➖ NeutralBenzinga•Sep 30, 2025, 11:14 AM
Aclaris Therapeutics' ATI-2138 Phase 2a Trial Results To Be Presented At 2025 EADV Congress In Paris For Moderate-To-Severe Atopic Dermatitis
📈 PositiveBenzinga•Sep 9, 2025, 11:20 AM
Frequently Asked Questions about ACRS
What is ACRS's current stock price?
Aclaris Therapeutics, Inc. (ACRS) is currently trading at $3.14 per share. The stock has moved +1.95% today.
What is the analyst price target for ACRS?
The average analyst price target for ACRS is $10.75, based on 1 analyst.
What sector is Aclaris Therapeutics, Inc. in?
Aclaris Therapeutics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is ACRS's market cap?
Aclaris Therapeutics, Inc. has a market capitalization of $0.34 billion, making it a small-cap company.
Does ACRS pay dividends?
No, Aclaris Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
BIOA
BioAge Labs, Inc.
$13.39
Mkt Cap: $0.5B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
MASS
908 Devices Inc.
$5.84
Mkt Cap: $0.2B
MDXH
MDxHealth S.A.
$3.15
Mkt Cap: $0.2B
NEO
NeoGenomics, Inc.
$11.83
Mkt Cap: $0.3B
OMI
Owens & Minor, Inc.
$2.84
Mkt Cap: $0.2B
SENS
Senseonics Holdings, Inc.
$6.15
Mkt Cap: $0.3B
XGN
Exagen Inc.
$6.43
Mkt Cap: $0.1B
Explore stocks similar to ACRS for comparison